Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a new, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones. The company uses its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates to improve the effectiveness of product candidates. The company’s leading product candidate, Aramchol, is being developed to serve as a disease modifying treatment for fatty liver disorders. For more information, visit the company’s website at www.galmedpharma.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.